MACIVIVA Report Summary

Periodic Reporting for period 2 - MACIVIVA (MAnufacturing process for Cold-chain Independent VIrosome-based VAccines)
Reporting period: 2016-11-05 to 2017-11-03

Summary of the context and overall objectives of the project

MACIVIVA stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines” and it is an EU Horizon 2020 Consortium (grant agreement No 646122) with a 42 months project involving four European and two Swiss partners that join their expertise for developing new thermostable vaccines. This Consortium brings together skills and competence from well-established Small Medium Enterprises (SMEs) in the field of virosome vaccines, drug formulations, spray drying, immunomonitoring assays, together with world-leading Contract Manufacturing Organizations (CMOs) with large scale manufacturing, freeze drying expertise, and packaging capabilities.

Click here to read the full report